Eton Pharmaceuticals Announces Acquisition of Rare Disease Product Candidate ET-600
March 15, 2023 06:50 ET
|
Eton Pharmaceuticals
-- Product is targeting rare pediatric endocrinology condition ---- Potential for NDA submission in Q2 2024 -- DEER PARK, Ill., March 15, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals (“Eton” or...
Eton Pharmaceuticals to Report Fourth Quarter 2022 Financial Results on Thursday, March 16, 2023
March 07, 2023 16:05 ET
|
Eton Pharmaceuticals
DEER PARK, Ill., March 07, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare...
Eton Pharmaceuticals Announces FDA Acceptance of NDA Response for Dehydrated Alcohol Injection
January 11, 2023 06:50 ET
|
Eton Pharmaceuticals
-- Product previously granted orphan drug designation for methanol poisoning ---- Application assigned a PDUFA date of June 27, 2023 -- DEER PARK, Ill., Jan. 11, 2023 (GLOBE NEWSWIRE) -- Eton...
Eton Pharmaceuticals Reports Third Quarter 2022 Financial Results
November 10, 2022 16:05 ET
|
Eton Pharmaceuticals
Q3 2022 revenue of $3.2 million, product sales and royalty revenue up 315% from prior year and 37% from Q2 2022Strong sales growth of ALKINDI SPRINKLE® and Carglumic AcidThird commercial product,...
Eton Pharmaceuticals to Report Third Quarter 2022 Financial Results on Thursday, November 10, 2022
November 02, 2022 16:05 ET
|
Eton Pharmaceuticals
DEER PARK, Ill., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare...
Eton Pharmaceuticals to Present at the LD Micro Main Event XV Conference
October 18, 2022 06:50 ET
|
Eton Pharmaceuticals
DEER PARK, Ill., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing...
Eton Pharmaceuticals Announces Acquisition of FDA-Approved Rare Disease Product, Betaine Anhydrous for Oral Solution
September 13, 2022 09:00 ET
|
Eton Pharmaceuticals
-- Expected to be accretive to 2023 earnings -- DEER PARK, Ill., Sept. 13, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical...
Eton Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference
August 30, 2022 16:05 ET
|
Eton Pharmaceuticals
DEER PARK, Ill., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing...
Eton Pharmaceuticals Reports Second Quarter 2022 Financial Results
August 11, 2022 16:01 ET
|
Eton Pharmaceuticals
Total Q2 2022 revenue of $7.4 million, up 139% from prior yearRecently launched ALKINDI SPRINKLE® and Carglumic Acid continue to show robust growthDivestiture of hospital products division to focus on...
Eton Pharmaceuticals to Report Second Quarter 2022 Financial Results on Thursday, August 11, 2022
August 02, 2022 08:00 ET
|
Eton Pharmaceuticals
DEER PARK, Ill., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare...